Evidence map›Paper›PMID 40941984›Full record

ReviewMolecules (Basel, Switzerland)2025

Metabolism, a Blossoming Target for Small-Molecule Anticancer Drugs.

Michela Puxeddu, Romano Silvestri, Giuseppe La Regina

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michela PuxedduLaboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0002-0024-596X
Romano SilvestriLaboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0003-2489-0178
Giuseppe La ReginaLaboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0003-3252-1161

Funding

Giuseppe La Regina MIUR PRIN 2022 2022TPPNTK (European Union - Next Generation EU)Giuseppe La Regina Sapienza University of Rome RG123188B4D193AEGiuseppe La Regina Sapienza University of Rome RM1241904EB3828DMichela Puxeddu Sapienza University of Rome AR224190786E7FA3Romano Silvestri AIRC IG 2020 n. 24703Romano Silvestri Sapienza University of Rome RG11816428A9B4D5Romano Silvestri Sapienza University of Rome RM120172A7EAD07C
6 · The paper itself

Abstract

Reprogramming is recognized as a promising target in cancer therapy. It is well known that the altered metabolism in cancer cells, in particular malignancies, are characterized by increased aerobic glycolysis (Warburg effect) which promotes rapid proliferation. The effort to design compounds able to modulate these hallmarks of cancer are gaining increasing attention in drug discovery. In this context, the present review explores recent progress in the development of small molecule inhibitors of key metabolic pathways, such as glycolysis, glutamine metabolism and fatty acid synthesis. In particular, different mechanisms of action of these compounds are analyzed, which can target distinct enzymes, including LDH, HK2, PKM2, GLS and FASN. The findings underscore the relevance of metabolism-based strategies in developing next-generation anticancer agents with potential for improved efficacy and reduced systemic toxicity.

Indexed as

Antineoplastic AgentsNeoplasmsSmall Molecule LibrariesAnimalsGlutamineGlycolysisHumansMetabolic Networks and PathwaysAntineoplastic AgentsGlutamineSmall Molecule Librariesaerobic glycolysiscancerfatty acid synthesisglutamine metabolismmetabolism

Identifiers

PMID40941984
PMCPMC12430568

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.